CELEBRATE Trial: Efficacy of Zalunfiban in the Prehospital Treatment of STEMI
Design, Results and Implications for Emergency Medical Services
The CELEBRATE Trial
The CELEBRATE trial evaluated the efficacy of zalunfiban, a novel glycoprotein IIb/IIIa (GPI) receptor inhibitor, and potentially represents a milestone in prehospital interventional cardiology. The study shows that subcutaneous administration of the drug at first medical contact in patients with ST elevation myocardial infarction (STEMI) improves patency of the infarct related artery before primary angioplasty. (1)
Among the main findings were improved initial coronary flow, a reduction in infarct size as assessed by high sensitivity troponin levels, and a decrease in cases of stent thrombosis and heart failure. With a number needed to treat (NNT) of 29, zalunfiban may represent a particularly interesting therapeutic option for emergency medical services (EMS), as it is currently one of the few drugs capable of providing such rapid platelet inhibition already at first medical contact.
Zalunfiban: Characteristics and Mechanism of Action
Unlike previously used GPI inhibitors such as abciximab or tirofiban, which require continuous intravenous infusion, zalunfiban was developed specifically for early and simple use.
Mode of administration: Rapid subcutaneous injection (less than 1 ml of solution).
Onset of action: Near complete platelet inhibition within approximately 15 minutes.
Pharmacokinetics: Short half life (approximately one hour), with recovery of platelet function within about two hours. This allows, if necessary, relatively early surgical procedures (for example CABG).
Mechanism of action: The drug blocks GPIIb/IIIa receptors, which represent the final common pathway of platelet aggregation.
Bridging role: In practice, it covers the initial time window before oral P2Y12 receptor inhibitors become fully effective.
Even when P2Y12 inhibitors are administered early, a practice that remains heterogeneous across the territory despite evidence of benefit (2), complete platelet inhibition may require several hours. In modern STEMI pathways, where the time between first medical contact and primary angioplasty is often relatively short, many patients reach the catheterization laboratory with still incomplete platelet inhibition. In this scenario, rapidly acting drugs such as zalunfiban may have a potential role.
Study Design
CELEBRATE is an international multicenter randomized double blind study conducted mainly in Europe (Netherlands, France, Czech Republic and Hungary) and, to a lesser extent, in Canada, Mexico and the United States.
Population and Protocol
Patients with suspected STEMI and symptom onset within four hours were enrolled.
Participants were randomized into three groups:
zalunfiban 0.11 mg/kg
zalunfiban 0.13 mg/kg
placebo
The large majority of patients (about 95%) also received standard therapy with aspirin, heparin and ticagrelor.
Eighty seven percent of patients were enrolled directly in the ambulance.
Study Endpoints
The primary endpoint was a hierarchical composite endpoint at 30 days including:
all cause mortality
stroke
reinfarction
acute stent thrombosis
new onset heart failure or hospitalization for heart failure
high sensitivity troponin peak greater than 30 times the upper normal limit
Among the secondary endpoints was patency of the infarct related artery upon arrival in the catheterization laboratory, assessed through corrected TIMI frame count.
Results
Clinical and Angiographic Efficacy
Data analysis showed superiority of zalunfiban compared with placebo across several parameters.
At the first angiography, patency of the infarct related artery (TIMI 2–3 flow) was present in 52.0% of patients treated with zalunfiban compared with 45.1% in the placebo group.
Corrected TIMI frame count, an indicator of coronary flow velocity, was significantly lower in the treated group (109 frames versus 176; p = 0.012), suggesting faster reperfusion before PCI.
Acute stent thrombosis was observed in 0.2% of patients treated with zalunfiban compared with 1.0% in the placebo group.
Overall, the analysis showed an absolute risk reduction of 3.5%, corresponding to an NNT of approximately 29 to prevent one event of the composite endpoint at 30 days.
Safety
No significant differences in major bleeding were observed between the zalunfiban group and the placebo group.
An increase in mild or moderate bleeding was observed in patients treated with zalunfiban, an expected finding given the potent antiplatelet effect of the drug. These events were not associated with increased mortality.
No increase in intracranial hemorrhage or clinically relevant gastrointestinal bleeding was observed.
Implications for EMS
The CELEBRATE trial also offers several interesting insights from an organizational and operational perspective for EMS.
First, subcutaneous administration makes the drug easily usable already at first medical contact, and simplicity and speed of administration are crucial elements in the prehospital setting.
In the trial, the mean time between drug administration and angiography was approximately 36 minutes, demonstrating that even relatively short intervals, such as those observed in urban EMS, may be sufficient to achieve a meaningful pharmacological effect before primary angioplasty.
From a logistical perspective, although the drug was stored under refrigeration during the study, stability data indicate that zalunfiban can be maintained at room temperature for prolonged periods, a characteristic that would facilitate its potential use on emergency vehicles.
More generally, this type of strategy fits well within the evolution of modern STEMI pathways, in which diagnosis should increasingly occur directly in the prehospital setting, possibly by personnel with advanced ECG interpretation skills and, we might add, aligned with the new OMI paradigm. In such a scenario, the availability of very rapidly acting drugs that can be administered immediately on site could become particularly relevant, transforming the interval between prehospital diagnosis and primary angioplasty into a true early therapeutic window.
Study Limitations
Despite the favorable results, the CELEBRATE trial has several limitations that must be considered when interpreting the data.
First, the enrolled population was relatively selected: patients with cardiac arrest, cardiogenic shock, dialysis, or chronic anticoagulant therapy were excluded. This means that the results may not be fully generalizable to some forms of myocardial infarction encountered in clinical practice.
In addition, most participants were male and of European origin, which may limit the applicability of the results to other populations.
Another aspect concerns the structure of the primary endpoint, which is a hierarchical composite endpoint including both hard clinical outcomes (death, stroke, reinfarction) and surrogate indicators such as troponin peak. This approach increases the statistical power of the study but makes interpretation of the overall clinical benefit more complex.
Finally, zalunfiban is not recommended in combination with intravenous fibrinolysis because of the high risk of bleeding. In settings where fibrinolysis still represents a primary reperfusion strategy, the role of the drug therefore remains to be clarified.
Conclusion
The rationale for zalunfiban becomes particularly interesting when viewed in the context of modern STEMI pathways.
Over the last twenty years, organizational efforts have focused primarily on reducing reperfusion times, progressively shortening the interval between first medical contact and primary angioplasty. However, this has highlighted a pharmacological limitation: many antithrombotic drugs routinely used require more time to become fully effective than the time needed to bring the patient to the catheterization laboratory.
The results of the trial suggest that the main effect of zalunfiban is to promote earlier coronary reperfusion before PCI, reducing thrombotic burden in the very early phases of myocardial infarction. Much of the observed benefit appears to be related to early reperfusion indicators and markers of myocardial injury, rather than to an isolated reduction in major clinical events. This mechanism recalls the historical concept of facilitated PCI, but with a pharmacological approach that is faster, reversible, and potentially better suited to the modern prehospital setting.
If this is the main mechanism of action, it becomes natural to view the prehospital phase from a different perspective, as a potential early therapeutic window.
Very rapidly acting drugs administered already at first medical contact could reduce thrombotic burden before the procedure and promote greater patency of the infarct related artery upon arrival in the catheterization laboratory, becoming an integral part of STEMI pathways within contemporary emergency services.
In this perspective, as occurred historically with fibrinolysis, reperfusion would no longer begin in the catheterization laboratory but in the minutes immediately following first medical contact.
References:
Van't Hof AWJ, Gibson CM, Rikken SAOF, Januzzi JL, Granger CB, van Beurden A, Rasoul S, Ruiters L, Vainer J, Verburg A, Arslan F, Jukema JW, Durieux M, Polad J, van Vliet R, van den Branden BJL, Magro M, Remkes W, Beelen J, Hermanides R, Tolsma R, Gosselink M, Vinereanu D, Chioncel V, van de Hoef TP, Boomars R, Arkenbout KE, van Houwelingen GK, Hengstman G, van de Wetering H, Pisters R, Kala P, Merkely B, Ecollan P, Lapostolle F, Giugliano RP, Welsh RC, Levy M, Arias-Mendoza A, Baron N, Cociorva D, Wittes J, Unger EF, Coller BS, Ten Berg JM, Montalescot G. Zalunfiban at First Medical Contact for ST-Elevation Myocardial Infarction. NEJM Evid. 2026 Jan;5(1):EVIDoa2500268. doi: 10.1056/EVIDoa2500268. Epub 2025 Nov 10. PMID: 41211981.
Gewehr DM, Carvalho PEP, Dagostin CS, Cardoso R, Kubrusly TBL, Kubrusly FB, Kubrusly LF. Pretreatment with P2Y12 inhibitors in ST-elevation myocardial infarction: A systematic review and meta-analysis. Catheter Cardiovasc Interv. 2023 Aug;102(2):200-211. doi: 10.1002/ccd.30750. Epub 2023 Jun 23. PMID: 37350287.
Fabris E, Korjian S, Coller BS, Ten Berg JM, Granger CB, Gibson CM, van 't Hof AWJ. Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thromb Haemost. 2021 Dec;121(12):1562-1573. doi: 10.1055/a-1414-5009. Epub 2021 Apr 30. PMID: 33677829; PMCID: PMC8604087.